商涌科技 builds a one-stop, full-cycle risk-management platform for the commercial health and life insurance market, anchored on a smart underwriting and risk-control engine (新机风控). It operates a claims advance service (新机安付) for inpatient and critical-illness coverage and a health-management platform (新机健康) offering medication access, consultations, chronic-disease management, and follow-up. The company has expanded into single-disease course management and in August 2021 launched a pediatric leukemia product (心守护) covering ages 28 days to 17 years, developed with top medical institutions and specialists. As of the article the firm has served 70+ insurance companies, nearly 500 personal-insurance products and provided risk-control services for about 20 million policy-holder touchpoints. In August 2021 商涌 completed a C round described as an "亿元" financing to deepen health-insurance management and single-disease product development, led by 招商健康 with 远毅资本 participating. The company emphasizes combining underwriting, claims capability and disease-course management to embed new therapy responsibilities into insurance products and to improve long-term survival expectations for clients.

Total raised

$15M

Funding rounds

1

Latest round

Series C

Latest activity

Aug 2021